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Abstract
Introduction: About 20% of renal angiomyolipomas (RAML) are associated with tuberous sclerosis com-
plex (TS). About 34–80% of patients with TS present with RAML. RAMLs associated with TS are at higher
risk of potentially life-threatening hemorrhage and hypovolemic shock. Only a few case reports of giant
RAML, defined as larger than 10 cm in diameter, and its management, have been reported.
Observation:  We present a 21 year old woman with abdominal distension over the last 2 years. A contrast-
enhanced CT scan revealed a giant RAML on the left side. Based on the presence of at least 3 major features of
the clinical diagnostic criteria of tuberous sclerosis complex, the diagnosis was made. An open nephrectomy
was performed. Therapeutic options described in literature are conservative management, medical treatment
with mTOR inhibitors, arterial embolization, radioablation and partial or total nephrectomy.
Conclusion:  In giant TS-associated RAML total nephrectomy, rather than conservative treatment, is the
treatment of choice in order to reduce the risk of potentially life-threatening bleeding.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SIntroduction
Renal angiomyolipomas (RAML) are rare, benign tumors consist-
ing of vascular elements, smooth muscle and adipose tissue. About∗ Corresponding author. Present address: Erasmus Medical Center Rotter-
dam. Doctor Molewaterplein 40 3015GD, Rotterdam, The Netherlands.
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lex (TSC) [1–3]. In the presence of bilateral lesions, one should
onsider a diagnosis of this neurocutaneous condition that also
auses benign tumors in the brain, heart, eyes, lung and skin [1].
maller RAMLs are often incidentally found on radiological exam-
nation, whereas RAMLs larger than 4 cm are at higher risk of
leeding [1,3]. RAML associated with TS are more likely to lead
o potentially life-threatening retroperitoneal hemorrhage due to
heir size, and multifocal and bilateral nature [1–3]. Embolization,
artial or total nephrectomy as treatment of larger RAMLs have
nd hosting by Elsevier B.V. This is an open access article under the CC
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ypomelanotic macule on the left chest >5 mm.
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Figure  2  Axial image from a contrast enhanced computed tomog-
raphy (CT) shows a primarily fat containing mass arising from the
left kidney suggestive of a giant angiomyolipoma (Hounsfield units of
−68,97).Figure  1  A. Facial angiofibromas. B. H
een described [3]. Only a few case reports about giant RAML,
hich is defined as larger than 10 cm in diameter, and its manage-
ent, have been published [4]. We present a case of giant RAML
n a young woman who presented with left abdominal pain and in
hom the diagnosis of tuberous sclerosis was made.
ase  presentation
 21 year old woman was referred to the urology department of
roote Schuur Hospital in Cape Town (South Africa) in November
017 because of weight loss and progressive abdominal disten-
ion over the last two years. No relevant medical or family history
as reported. An ultrasound of the kidneys which was done at the
eferring hospital reported a big solid mass on the left side of the
bdomen.
kin inspection showed multiple (>10) facial angiofibromas and 4
ypopigmented macules on the chest, lower back and right buttock
Fig. 1). Multiple skin lesions with a ‘confetti’ appearance were seen
n both arms and legs. No other dermatologic or dental features
f TS were seen. Inspection of the abdomen showed abdominal
istension on the left side. A large non-tender mass was palpated in
he left upper quadrant extending beyond the midline.
aboratory results showed anemia (Hb of 9,4 g/dl) and microscopic
ematuria. A contrast enhanced CT-scan of the abdomen revealed a
eterogeneous left renal mass with areas of soft tissue and fat compo-
ents (Hounsfield units of −68,97), measuring 123,0 ×  159,4 mm
Fig. 2). The right kidney showed multiple cortical hypodensities
ith the largest measuring 11 mm. Both lesions were reported as
uspicious for angiomyolipoma (AML).
lood transfusion with 2 units of packed cells was given.
 left radical nephrectomy was performed through a chevron
ncision under general anesthesia. A mass with a diameter of
90 mm ×  215 mm ×  120 mm and a weight of 3,58 kg was removed
Fig. 3). The procedure was complicated intraoperatively by pan-
reatic tail injury requiring distal pancreatectomy. She developed a
ancreatic leak which required a stay in the Intensive Care Unit. The
eak resolved spontaneously. The patient was discharged 3 weeks
fter surgery.
Figure  3  Excised tumor of 3,58 kg, showing a mixture of mature
adipose tissue and thick walled blood vessels.
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Figure  4  A. Histopathological examination demonstrated smooth muscle, mature adipose tissue and thick walled blood vessels (hematoxylin and
eosin stain, magnification ×40). B. Epithelioid smooth muscle cells emanating from blood vessel walls (haematoxylin and eosin stain, magnification
×200).
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aFigure  5  Axial Magnetic resonance imaging (MRI) (T2 weighted) of
small subependymal nodule (indicated by white arrows and black arrow
Histopathology of the mass confirmed an angiomyolipoma con-
sisting of a combination of spindled smooth muscle cells, mature
adipose tissue and thick walled blood vessels. Smooth muscle cells
which emanated from the walls of the blood vessels frequently had
an epithelioid morphology (Fig. 4). A few of the many lymph nodes
submitted contained a combination of both smooth muscle and adi-
pose tissue components of angiomyolipoma. Immunohistochemical
staining was not required.
Further investigation with MRI brain showed multiple cortical and
subcortical T2 weighted white matter hyperintensities and multiple
predominantly right ventricular small subependymal nodules. No
subependymal giant cell astrocytoma was seen (Fig. 5). Expectative
management was performed since neurological investigation was
negative for mental retardation or epilepsy.
Ophthalmologic consult revealed no lesions indicative of a retinal
hamartoma. Electrocardiogram did not show any cardiac arrhyth-
mias therefore, echocardiography was not performed. Genetic
screening unfortunately could not be done due to non-availability
of the service.
According to the recommendations of the 2012 International Tuber-
ous Sclerosis Complex Consensus (ITSCC) our patient meets 4
a
w
[
flrain, demonstrating white matter hyperintensities and right ventricular
spectively).
ajor criteria to confirm the diagnosis of TSC: >2 angiomyolipo-
as, >3 facial angiofibromas, 4 hypopigmented macules (>5 mm
iameter) and subependymal nodules in the brain [5] (Table 1).
iscussion
S is an autosomal dominant disease, most often caused by a muta-
ion of the TSC1  or TSC2  gene, with incomplete penetrance, which
ffects multiple organ systems. Prevalence in the literature varies
rom 1/6000 to 1/12000 individuals [1,6–8]. About 34–80% of
atients with TS present with renal angiomyolipoma (RAML) and
bout 20–30% of RAML cases are associated with TS [9]. RAML
ssociated with TS typically manifest at a younger age, are bilat-
ral and multifocal, grow with time, and are more likely to lead
o potentially lifethreatening hemorrhage [10]. Giant RAMLs are
efined as larger than 10 cm in diameter [4]. Very little literature
s written about giant RAMLs. Our patient presented with abdom-
nal distension for 2 years, and pain in the abdomen and back for
 months, without signs of hypovolemic shock. She did not have
ny urinary symptoms. Patients with TS-associated giant RAMLs
s reported by Lin et al., Katz et al. and Tsutsumi et al. presented
ith cyclic left flank pain, general fatigue, and epigastric fullness
2,11,12]. About 10% of patients with RAML present with acute
ank pain, haematuria, and signs of internal bleeding which is char-
178 
Table  1  Clinical diagnostic criteria of TSC.
Tuberous sclerosis complex diagnostic criteria update:
recommendations of the 2012 International Tuberous Sclerosis
Complex Consensus Conference
Major features
1. Hypomelanotic macules (≥3, at least 5-mm diameter)
2. Angiofibromas (≥3) or fibrous cephalic plaque
3. Ungual fibromas (≥2)
4. Shagreen patch
5. Multiple retinal hamartomas
6. Cortical dysplasias*
7. Subependymal nodules
8. Subependymal giant cell astrocytoma
9. Ca rdiac rhabdomyoma
10. Lymphangioleiomyomatosis (LAM)†
11. Angiomyolipomas (≥2)†
Minor features
1. “Confetti” skin lesions
2. Dental enamel pits (>3)
3. Intraoral fibromas (≥2)
4. Retinal achromic patch
5. Multiple renal cysts
6. Nonrenal hamartomas
a
r
T
a
h
T
a
t
i
I
e
a
q
a
e
A
t
a
s
o
H
r
r
u
t
(
t
p
b
r
b
t
i
h
i
i
a
t
e
t
i
T
t
T
r
i
a
t
H
i
e
a
h
t
T
n
s
w
n
b
o
a
S
r
R
i
C
T
c
n
o
b
t
S
m
C
W
A
J
lDefinite diagnosis: Two major features or one major feature with ≥2
minor features
cteristic of ‘Wünderlich Syndrome’; a urological emergency of
etroperitoneal hemorrhage which manifests as hypovolemic shock.
he presence of intratumoral aneurysms >5 mm in tumors >4 cm has
lso been reported as a risk factor for spontaneous retroperitoneal
emorrhage [13].
reatment options for RAML described in the literature include
ctive surveillance with reimaging, partial/total/radical nephrec-
omy, radiofrequency- or cryoablation and selective mTOR
nhibitors such as everolimus.
n general, indications for intervention for renal AML are the pres-
nce of symptoms, high risk of bleeding and size (>4 cm), even when
symptomatic [14]. However, the indication of tumor size has been
uestioned recently. Kuusk et al. showed that only tumors >6 cm are
t a higher risk for bleeding while Chronopoulos et al. showed that
ven tumors <8 cm tend to be asymptomatic [4,15].
ctive surveillance seems to be appropriate for tumors smaller
han 4 cm only [16,17]. On the contrary, Ouzaid et al. stated that
ctive surveillance can also be an option in tumors >4 cm. They
uggest that the historically quoted threshold of 4 cm may lead to
vertreatment [18].
owever, it must be noticed that the above studies included both spo-
adic and TS associated RAML. Hence, larger lesions are at higher
isk of bleeding, but there is no consensus on what size should be
sed as the cutoff for intervention. In this case, treatment indica-
ion was clear, since the patient had a symptomatic giant RAML
290 mm ×  215 mm ×  120 mm). Surgical treatment seems to be the
reatment of choice in larger RAML, if renal malignancy is sus-
ected or in cases of hemorrhage [19]. Since RAML in TS is often
ilateral and multifocal, and is known to have a higher recurrence
ate, nephron sparing surgery (NSS) is highly recommended either
y selective embolization or partial nephrectomy [15,16,20]. Selec-
s
M
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ive arterial embolization (SAE) is now a first-line treatment option
n RAML and particularly used in cases of acute hemorrhage and
emodynamic shock [20]. Compared to surgical treatment, the most
mportant advantage is sparing of the renal parenchyma and the min-
mally invasive nature of the procedure. However, recurrence rates
fter SAE in TS associated RAML vary from 11 to 40%, hence con-
inuous follow-up is required [21]. Moreover, in this case selective
mbolization was technically impossible since the AML substituted
he majority of the parenchyma of the left kidney. The same technical
mpossibility applies for a partial nephrectomy.
he most recently introduced treatment option in RAML is targeted
herapy which inhibits the mammalian target of rapamycin (mTOR).
he aim of the treatment is to reduce tumor progression and promote
egression of existing tumor. According to recent literature mTOR
nhibitors are effective and safe in regulating asymptomatic TS
ssociated RAML >3 cm not amendable to other treatment. Addi-
ionally, renal parenchyma will be spared in this treatment [22].
owever, Cabrera-Lopez et al. suggest that the effect of mTOR
nhibitors is unlikely to be durable [23]. Moreover, everolimus for
xample is associated with stomatitis (48%), nasopharyngitis (24%),
cne-like skin lesions (22%), headache (22%), cough (20%) and
ypercholesterolemia (20%). Long-term consequences of mTOR
oxicity remain unknown [22]. Since our patient had a symptomatic
S associated RAML >3 cm, treatment with mTOR inhibitors was
ot appropriate in this case. However, this patient had asymptomatic
maller lesions (biggest lesion was 11 mm) in the other kidney as
ell. At this stage treatment with mTOR inhibitors for the right kid-
ey is premature since the lesions are <3 cm. mTOR inhibitors can
e considered when lesions are >3 cm. We will see the patient at
ur outpatient clinic in 6 months for follow-up, with a CT scan in
dvance.
pecific research on treatment options for giant RAML has not been
eported so far. Owing to the size of the tumor in giant TS-associated
AML we assume mTOR inhibitors might potentially play a role
n their management, alongside surgical treatment.
onclusion
he present case report highlights two important aspects for
linicians. First, in giant TS-associated RAML, partial or total
ephrectomy, rather than conservative treatment, is the treatment
f choice in order to reduce the risk of a potentially life-threatening
leed. However, in this case report we would like to emphasize the
echnical challenge of nephron sparing treatment in giant RAML.
econd, future research is needed to further explore the role of
TOR inhibitors in the treatment of giant RAML.
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